The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis.
 
Shilpa Grover
Employment - UpToDate
Honoraria - Novartis (I)
 
Amitabh Srivastava
No Relationships to Disclose
 
Sonia Friedman
No Relationships to Disclose
 
Elizabeth Iannotti Buchbinder
Employment - Biodesix (I); Sanofi (I); Smith & Nephew (I)
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Lilly; Merck; Novartis
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Osama E. Rahma
Leadership - Outcomes4me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; Leerink; Leerink; Merck; PureTech; Putnam Associates
Research Funding - Amgen (Inst); Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech